Discovery Stage Milestone Payments
Executive SummaryMilestone payments in discovery-stage deals have been falling within a limited range, consistent with a trend in dealmaking at other stages. But the real variation comes not in the value of the milestone payments, but in the disparate levels of assurance of the milestones being reached.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.